---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-126502"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2026-11-13T11:27:13+00:00"
generated_at: "2026-11-13T11:30:02.307050+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Rezolute's Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism hits primary endpoint

## Summary
- 13 of 16 participants met the ≥50% GIR reduction responder criterion, including 12 with complete IV glucose discontinuation; threshold was ≥9 responders (≥56%).
- Primary endpoint achievement based on preliminary results from a November 5, 2026 data evaluation; topline and statistical analysis expected by mid-December 2026.
- One participant discontinued early to enter home hospice and died a week later from cancer progression; classified as a non-responder.
- Enrollment: 16 participants — 4 with non-islet cell tumors and 12 with insulin-secreting malignant insulinomas; ersodetug dosed 9 mg/kg weekly for 8 weeks.
- Ersodetug well-tolerated with no drug-related safety findings; CEO Nevan Elam targets FDA discussions in Q1 2027 for congenital and tumor HI.

## SEC filing metadata
- accession: 0001104659-26-126502
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2026-11-13T11:27:13+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465926126502/0001104659-26-126502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465926126502/tm2627558d10_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-126502
- JSON: https://secwatch.observer/filing/0001104659-26-126502.json
- Plain text: https://secwatch.observer/filing/0001104659-26-126502.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.